{
    "clinical_study": {
        "@rank": "36966", 
        "arm_group": [
            {
                "arm_group_label": "Alpha1-PI 180 mg/kg/wk, 26 weeks", 
                "arm_group_type": "Experimental", 
                "description": "180 mg/kg weekly infusions of Alpha1-PI for 26 weeks."
            }, 
            {
                "arm_group_label": "90 mg/kg/wk Alpha1-PI, 26 weeks", 
                "arm_group_type": "Experimental", 
                "description": "90 mg/kg weekly infusions of Alpha1-PI for 26 weeks."
            }, 
            {
                "arm_group_label": "Placebo, 26 weeks", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Weekly infusions of placebo for 26 weeks."
            }, 
            {
                "arm_group_label": "180 mg/kg/wk Alpha1-PI, 13 weeks", 
                "arm_group_type": "Experimental", 
                "description": "180 mg/kg weekly infusions of Alpha1-PI for 13 weeks."
            }, 
            {
                "arm_group_label": "90 mg/kg/wk Alpha1-PI, 13 weeks", 
                "arm_group_type": "Experimental", 
                "description": "90 mg/kg weekly infusions of Alpha1-PI for 13 weeks"
            }, 
            {
                "arm_group_label": "Placebo, 13 weeks", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Weekly infusions of placebo for 13 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of\n      human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years\n      old) and teens/adults (ages 12-35 years old) with new onset Type 1 Diabetes Mellitus (T1DM).\n       The purpose of this study is to evaluate the safety and efficacy of four dosing regimens of\n      human plasma-derived alpha1-PI in T1DM."
        }, 
        "brief_title": "Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin Deficiency", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of T1DM according to the ADA criteria.\n\n          -  Current use of injected insulin therapy and one positive result on testing for any of\n             the following antibodies (If not currently on insulin therapy, must have positive\n             result for at least two of the below antibodies):\n\n               -  Anti-islet-cell antibodies (islet cell antigen 512, insulinoma associated\n                  protein 2),\n\n               -  Anti-glutamic acid decarboxylase antibodies, or\n\n               -  Anti-insulin antibodies (unless received insulin therapy for > 7 days).\n\n          -  Body Mass Index (BMI) \u2264 25 kg/m2 for adults (\u2265 20 years of age) OR < 85th percentile\n             in accordance with the Centers for Disease Control BMI assessment for children and\n             teens (2 through 19 years old).\n\n        Exclusion Criteria:\n\n          -  History of or current diabetic retinopathy, neuropathy, or nephropathy.\n\n          -  Known thrombophilia or history of thrombosis.\n\n          -  Malignant disease (including malignant melanoma; however, other forms of skin cancer\n             are allowed) within five years of randomization.\n\n          -  Active Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, or Human\n             Immunodeficiency Virus infection.\n\n          -  History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI\n             preparation or other blood product(s).\n\n          -  Known selective or severe Immunoglobulin A deficiency.\n\n          -  Elevated liver enzymes (aspartate transaminase, alanine aminotransferase, and\n             alkaline phosphatase) equal to or greater than 2.5 times the upper limit of normal.\n\n          -  Therapy with exenatide or any other agents that stimulate pancreatic \u03b2 cell\n             regeneration or insulin secretion, or any antidiabetic agents (oral or parenteral)\n             other than insulin within three months prior to screening.\n\n          -  Use of omega-3 fatty acid supplements, including fish oil, within seven days prior to\n             screening.\n\n          -  Current or planned therapy with inhaled insulin, if it becomes available.\n\n          -  Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (e.g.,\n             10 mg every 2 days) within the 4 weeks prior to randomization.  It is recommended to\n             maintain the same dose throughout the study.\n\n          -  Treatment with immunosuppressants or cytostatic agents within 6 months of\n             randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093221", 
            "org_study_id": "GTI1302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Alpha1-PI 180 mg/kg/wk, 26 weeks", 
                    "180 mg/kg/wk Alpha1-PI, 13 weeks"
                ], 
                "intervention_name": "180 mg/kg Alpha1-PI", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Alpha1-antitrypsin", 
                    "Prolastin-C", 
                    "Alpha1-Proteinase Inhibitor (human), Modified Process", 
                    "Alpha-1 MP"
                ]
            }, 
            {
                "arm_group_label": [
                    "90 mg/kg/wk Alpha1-PI, 26 weeks", 
                    "90 mg/kg/wk Alpha1-PI, 13 weeks"
                ], 
                "intervention_name": "90 mg/kg Alpha1-PI", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Alpha1-antitrypsin", 
                    "Prolastin-C", 
                    "Alpha1-Proteinase Inhibitor (human), Modified Process", 
                    "Alpha-1 MP"
                ]
            }, 
            {
                "arm_group_label": [
                    "Placebo, 26 weeks", 
                    "Placebo, 13 weeks"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor", 
                "Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Type 1 Diabetes Mellitus", 
            "Alpha1-Proteinase Inhibitor", 
            "Beta Cell", 
            "Alpha1-Antitrypsin"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tarzana", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ventura", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Idaho Falls", 
                        "country": "United States", 
                        "state": "Idaho"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dearborn", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus", 
        "overall_contact": {
            "email": "Ed.Corsi@grifols.com", 
            "last_name": "Ed Corsi"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "C-peptide concentration during mixed meal tolerance test with high protein energy drink.  \"Dose\" for timeframe referes to intake of high protein energy drink.", 
            "measure": "C-peptide Area Under the concentration-time Curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "10 min pre-dose, immediately pre-dose, 15, 30, 60, 90, and 120 minutes post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects who discontinue due to Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change from baseline for HbA1c levels", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1 (Baseline), 14, 27, 39, 52, 69, 87, and 104"
            }, 
            {
                "description": "Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.", 
                "measure": "Number of severe hypoglycemic episodes", 
                "safety_issue": "No", 
                "time_frame": "104 weeks"
            }, 
            {
                "measure": "Serum alpha1-PI AUC", 
                "safety_issue": "No", 
                "time_frame": "Immediately prior to last infusion, immediately after, 15 and 30 minutes after, and 1, 3, 8, 24, 48, 120, 168, 240, 336, 408, and 504 hours after last investigation product infusion"
            }, 
            {
                "description": "Blood samples for determination of trough total serum alpha1-PI concentration will be drawn prior to the Week 12 and 13 infusions or the Week 25 and 26 infusions depending on the randomized treatment group.", 
                "measure": "Mean trough serum alpha1-PI", 
                "safety_issue": "No", 
                "time_frame": "Immediately prior to the Week 12 and 13 or Week 25 and 26 investigational product infusions"
            }
        ], 
        "source": "Grifols Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grifols Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}